NEW APPROACHES TO PEDIATRIC DILATED CARDIOMYOPATHY IN CURRENT PRACTICE

Assoc. Prof. Amalia Fagarasan, MD, PhD
Assist. Prof. Maria Oana Sasaran, MD, PhD

Department of Pediatrics III, “George Emil Palade” University of Medicine,
Pharmacy, Sciences and Technology of Târgu Mureș, Romania

ABSTRACT

Progresses to radiologic and molecular genetics fields created the premises for the development of a new, descriptive classification system of cardiomyopathies, known under the MOGE (S) acronym, with the help of informations provided by molecular genetic testing that led to better knowledge regarding their physiopathogenic backgrounds, the implementation of a descriptive, nosologic phenotype-genotype and the establishment of an accurate clinic and genetic diagnosis. Dilated cardiomyopathy (DCM) in children remains the most frequent type of cardiomyopathy, representing an important cause of death in the first 2 years of life, and its impact at neonatal age is not fully understood, due to the low number of studies regarding its real incidence. Its death rate is high, 10 % of neonatal deaths of cardiac origin being caused by DCM. Ecocardiography helps in establishing the diagnosis and evolution and therapy monitoring. Modern ultrasound techniques (tissue Doppler or speckle tracking), as well as 3D ultrasound provide highly accurate data. Paraclinical assessments, such as neuropeptides (BNP, NT-proBNP), have both diagnostic and prognostic roles. Medical treatment recommended for congestive cardiac failure symptom relief consists of angiotensine converting enzyme inhibitors (the long acting ones are preferred – Lisinopril), mineralocorticoid receptor antagonists and beta-blockers (Bisoprolol), which act by decreasing the afterload, limiting the ventricular remodelling process and can easily be administered, in unique dose. Novel therapeutic approaches have aroused, such as regenerative therapy of cardiomyocytes. Cardiac transplant remains a therapeutic option limited by a small number of donors.

Conclusions. Diagnostic and therapeutic approach of DCM have been substantially improved, integration in current practice of new diagnostic methods and regenerative therapeutic approaches can change the prognostic perspective of this disease.

Keywords: dilated cardiomyopathy, children, cardiac regenerative therapy

INTRODUCTION

The importance of myocardic pathology as a cause of pediatric death of cardiac origin cannot be foreseen. Cardiomyopathies are defined as anomalies with initial structural and functional involvement of the myocardium, after excluding conditions which evolve to severe myocardial dysfunction in the absence of proper treatment (serious cardiac congenital anomalies, arterial hypertension) (1).

A subject of great interest is the classification of cardiomyopathies, the one performed on specific morfo-functional criteria classifying it into primary types with familial (genetic) and non-familial (non-genetic) subtypes (2). Progresses in the molecular genetic field allowed the opening towards new perspectives regarding etiopathogenics, diagnosis and treatment. Starting with 2013 a new, much more elaborated classification system has been implemented, known under the MOGE (S) acronym, a descriptive system in which informations provided by molecular genetic testings created the premises towards a better knowledge of physiopathological basis, implementation of a descriptive nosologic phenotype-genotype and establishment of an accurate clinic and genetic diagnosis (3,4). A detailed, descriptive diagnosis is concluded for each patient, depending on their specific clinic and genetic characteristics (phenotype/genotype) and the management of cardiomyopathies becomes personalised (target of future medicine) (5). Genotypes drive the diagnosis and therapeutic decisions and can in equal matter help conduct a correct screening for first degree relatives (genetic, predictive „waterfall”

Corresponding author:
Assoc. Prof. Amalia Fagarasan, MD, PhD
E-mail: amalia_fagarasan@yahoo.com
test establishes a prediction index and enhances the development of a follow-up strategy regarding lethal arrhythmia risk in case of „malignant” mutations or sudden death risk, as well as prediction of disease transmission to the successors) (6).

**EPIDEMIOLOGY AND PATHOPHYSIOLOGY**

Dilated cardiomyopathy (DCM) in children remains by far the most frequent type, comprising more than 50 % of the total number of cardiomyopathies and is one of the most frequent causes of congestive cardiac failure (CCF), being responsible for a high death rate in the first two years of life (7,8). Its unanimously accepted definition is based upon cardiac ultrasound criteria: dilation and alteration of the systolic function of the left ventricle, ultrasonographically quantified through an ejection fraction (EF) < 40 % and a telediastolic dimension with a Z score >2 (9). A peculiarity of pediatric pathology is represented by the epidemiologic features of cardiomyopathies in newborns, difficult to define due to the low number of studies, with an estimated incidence of around 1: 10.000 live births, but responsible for approximately 10% of neonatal deaths of cardiac origin (9,10). Inflammatory diseases of the myocardium, regardless of age, are one of the main causes of DCM (11). Relationship between myocarditis and DCM is uncertain, but a high number of studies and experiments conducted on animals explains the three stage evolution from the initial episode (viral infection) to the constitution of cardiomyopathy (12):

- **Initial stage** is characterised by an initial myocardial insult (viral infection in most of the cases), which is silent from a clinical point of view and difficult to diagnose; most frequent viral infections associated with DCM are caused by Coxsackie type B and Adenoviruses (13).
- **Stage two**, in which triggering of autoimmune mechanisms leads to a progressive myocardial deterioration, with first clinical manifestations of CCF and diagnosis of the disease (14).
- **Stage three**, in which DCM is already installed, with typical symptoms (14).

Diagnostic and therapeutic implications of each of these phases are certainly pretty different. CDM pathogenics is believed to result from an association between myocyte disfunction mediated directly by the virus and immune response (tissular mediated lesion). For a correct diagnosis identification of viral genoma inside myocardial tissue with the help of polymerase chain reaction (PCR) is crucial, but difficult to achieve in daily practice (15,16).

**DIAGNOSTIC TOOLS – IMPORTANCE OF ECHOCARDIOGRAPHY**

Suggestive clinical tableau at low ages is the one of CCF: feeding difficulties, excessive sweating, tachypnea, tachycardia, cold extremities and weak pulse (signs of decreased cardiac output). Following signs and symptoms can appear in older ages: dyspnea during effort and at rest, pale-cyanotic extremities, heptomegaly ± pain in the right hypochondrium, anorexia, peripheral edema and anasarca, in advanced stages (ascytes, pericarditis, pleuresia) (17).

M, 2D and Doppler ultrasound facilitates diagnosis and follow-up of therapy efficacy on ventricular function. Cardiac ultrasound brings in a series of supplemental data, as it allows the assessment of: sphericity index (ratio between longitudinal/transverse diameter of left ventricle), with values <1,5 representing an indicator of abnormal remodelation, the end-diastolic and end-systolic volumes of the left ventricle, depending on the body surface (increased values), right ventricle function, mitral and tricuspid valve regurgitation, as well as dp/dt ratio, lower values than 600 being indicating of severe systolic dysfunction of the left ventricle. Intracavitary thrombi or spontaneous echo contrast appear due to severe ventricular dysfunction. Today, we benefit from advanced technologies and modern evaluation methods: tissue Doppler echocardiography or speckle tracking which allow calculation of global and segmental function of the left ventricle. High precision measurements of left ventricular and atrial volumes, as well as assessment of right ventricular function can be performed using 3D ultrasound (18,19).

Paraclinical examinations, such as neuropeptides (brain natriuretic peptide – BNP, N-terminal pro-brain natriuretic peptide – NT-proBNP), with levels which are bigger than normal, are recommended as quantification methods with high diagnostic and prognostic value (20,21).

The following will be supervised: renal, hepatic, endocrine function (for possible thyroid dysfunctions) (22). Autoimmune processes will be investigated (23). Proteinuria, in combination with hyponatremia and increased urinary density are suggestive of cardiac decompensation (22).

**TREATMENT – FROM CLASSICAL APPROACH TO NOVEL REGENERATIVE AND BRIDGING THERAPY**

Treatment of CCF using angiotensin converting enzyme inhibitors (preferably long-acting), angiotensin receptor blockers (Spironolactone) and beta-
blocks is considered the best option, as these drugs act by decreasing cardiac output and limiting ventricular remodeling process (24). In the situation of chronic, decompensated CCF, which no longer responds to chronic oral medication, initiation of intravenous, inotropic therapy is recommended, which includes Levosimendan, phosphodiesterase inhibitors-Milrinone, Dobutamine, Dopamine, as well as parenteral diuretics (Furosemide) (25). New therapeutic methods, recommended according to the experience of the Giessen centre, from Germany, include pulmonary artery banding for functional regeneration in children with DCM, younger than 6 years (with better results in those younger than 3 years). This procedure could improve the prognosis of the disease and is recommended especially in cases awaiting a cardiac transplant, with cardiac failure NYHA/Ross III or IV, with severe impairment of left ventricular function (EF < 30%), who have not exhibited a good response to inotropic, intravenous treatment given in maximal doses and chronic optimal medical treatment, and who do not have any other type of structural cardiac abnormalities, including a normal right ventricle function (preferably quantified by an MRl) (26). Heart transplant remains a limited therapeutic option (low number of donors compared to the very high demand) and is reserved to children who have not responded to inotropic parenteral treatment given in maximal doses nor to optimal chronic medical treatment (7). Other treatment options which have risen survival rate in severe cases are extracorporeal membrane oxygenation – ECMO and ventricular assist device (produced by Berlin Heart) –, which are devices available for bridging to heart transplantation (27,28). Treatment methods available in adult populations, such as biventricular cardiac resynchronization therapy and cardioverter implanting for ventricular arrhythmias with potentially malignant outcome can also be used in children, but experience is limited on this matter (29).

**EVOLUTION AND PROGNOSIS**

Evolution of DCM varies, depending on its etiology (7).

Prognosis is influenced by factors which negatively impact the progression of the disease: symptoms corresponding to NYHA/Ross class III or IV, presence of endomyocardial fibroelastosis, progressive mitral valve insufficiency, right ventricular dilation and dysfunction, arrhythmias or conduction disorders and EF lower than 30% (30).

**CONCLUSIONS**

Therapeutic and diagnostic approach of DCM underwent substantial improvements, whereas integration into daily practice of new diagnosis methods and regenerative treatment options can change the prognostic perspective of the disease.

**REFERENCES**